Department of Medical Services and Techniques, Vocational School of Health Services, Adiyaman University, Adiyaman, Turkey.
Mutat Res Rev Mutat Res. 2023 Jan-Jun;791:108456. doi: 10.1016/j.mrrev.2023.108456. Epub 2023 Mar 21.
From a single restriction fragment length polymorphism analysis to next generation sequencing analysis that screens the entire human genome, testing for genomic variations provides a great and robust approach to cancer testing. Non-coding RNAs have been shown to have a major impact on the development and progression of human cancers, including prostate cancer. However, the low stability of these molecules under laboratory conditions has made their clinical utility challenging, as in the case of PCA3 long non-coding RNA. Since testing for variations in genomic regions encoding non-coding RNAs offers a promising approach for cancer testing, identification and interpretation of single nucleotide polymorphisms associated with prostate cancer susceptibility is of great interest. Accordingly, here, for the first time, we review and discuss current available knowledge about genomic variation of long non-coding RNA molecules in prostate cancer.
从单一的限制性片段长度多态性分析到对整个人类基因组进行筛查的下一代测序分析，检测基因组变异为癌症检测提供了一种强大的方法。非编码 RNA 已被证明对人类癌症的发展和进展有重大影响，包括前列腺癌。然而，这些分子在实验室条件下的低稳定性使得它们的临床应用具有挑战性，就像 PCA3 长非编码 RNA 一样。由于检测编码非编码 RNA 的基因组区域中的变异为癌症检测提供了一种很有前途的方法，因此鉴定和解释与前列腺癌易感性相关的单核苷酸多态性是非常有意义的。因此，在这里，我们首次回顾和讨论了目前关于前列腺癌中长非编码 RNA 分子的基因组变异的现有知识。
